Jnana launches with $50M series A

Jnana Therapeutics Inc. (Boston, Mass.) launched with a $50 million series A round from existing investors Polaris Partners and Avalon Ventures and new investors Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.

The biotech is creating a small molecule drug discovery platform targeting the solute carrier (SLC) family of transporters, with a focus on immuno-metabolism, lysosomal function and mucosal defense for immuno-oncology, inflammatory disorders and neurological diseases...